The Tabula Sapiens program aims to take the organs from the same individual controls for genetic background, age, environment, and epigenetic effects to allow the detailed analysis and comparison of cell types that are shared between tissues.
Swiss audiology tech firm Sonova is partnering French hearing-loss biotech Sensorion to study the genetics of age-related hearing loss in a large, long-term study of newly diagnosed individuals.
A research team based at McMaster University in Canada has developed an algorithm that can design more accurate probes to detect infectious disease pathogens in mixed samples and help avoid time consuming bulk sequencing.
An innovative bioinformatics approach developed at MIT and the Institute Pasteur allows genomes to be assembled within minutes on a standard desktop computer, a process that normally takes many hours and uses high amounts of computing power.
There are currently no predictive biomarkers for long-term survival after neoadjuvant immunotherapy for lung cancer. However, identifying patients with non-small lung cancer (NSCLC) who obtain long-term benefit from IO is essential to optimize treatment.
Oxford Nanopore first entered DNA/RNA sequencing in 2014, with an early version of its technology offering the ability to sequence long fragments of DNA, portability, direct detection of DNA molecules, and real-time data streaming for rapid insights and dynamic workflows.
Researchers at the Okinawa Institute of Science and Technology Graduate University measured the levels of 124 different metabolites in whole blood and found that 33 metabolites, split into five different sub-groups, correlated with dementia.
A new research consortium, which will be given $185M by the National Institutes of Health over 5 years, will try to determine how variations in the genome are actually affecting the body.
The collaboration will leverage Foundation Medicine’s FoundationSmartTrial solution which identifies potential clinical trial candidates based on the results of tissue or liquid biopsy testing. Patients will then be referred to Science 37 for enrollment and management of the patients via its Decentralized Clinical Trial Operating System.
Medical genetics leader Invitae will acquire patient-data focused tech company Ciitizen in a deal worth approximately $325 million, to help further its plans to democratize genetic testing and make it accesible to more people.